BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 25, 2002
 |  BioCentury  |  Strategy

Alkermes buys into specialty pharma

Alkermes Inc.'s acquisition of Reliant Pharmaceuticals LLC checks two boxes in ALKS's bid to become a big cap specialty pharmaceutical company. The deal puts ALKS within spitting distance of the top tier of biotech companies valued above $3 billion, and, perhaps more importantly, provides the company with the marketing infrastructure to compete for in-licensing drugs.

"There's a major shift to size and scale in this transaction," said CEO Richard Pops. "We go from being one of the more expensive drug delivery/development companies to the best value in the specialty pharma space. It's a different business now. It's no longer a drug development business - it's now a commercialization story."

ALKS will issue 31.1 million shares of stock to acquire the remaining 81% of Reliant (Liberty Corner, N.J.) it did not already own (see B2).

Using ALKS's Friday close of $27.24, the stake is valued at $847.2 million, and would give ALKS...

Read the full 745 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >